Pilot study to evaluate the safety and feasibility of intracoronary CD133⁺ and CD133⁻ CD34⁺ cell therapy in patients with nonviable anterior myocardial infarction

Abstract

Intracoronary infusion of selected CD133(+) and CD133(-)CD34(+) progenitor cells to a previously infarcted and nonviable anterior wall is safe, and results in sustained improvement in segmental myocardial perfusion and in favorable left ventricular remodeling.